GaryJRichmondMDFACP, FCCP

PubMed

• ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.
  Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Ward D, Zhao HH, Ross LL, Shaefer MS, ARIES Study Team> ;HIV clinical trials.
• 11 citations
  Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results.
  Anthony M. Mills, Gary Richmond, Cheryl L. Newman, Olayemi Osiyemi, Jerry Cade, Cynthia Brinson, Jerome De Vente, David A. Margolis, Kenneth Sutton, Viviana Wilches, S...> ;AIDS. 2021 Oct 13
• 37 citations
  Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase ...
  Hans Jaeger, Edgar T. Overton, Gary Richmond, Giuliano Rizzardini, Jaime Andrade-Villanueva, Rosie Mngqibisa, Antonio Ocampo Hermida, Anders Thalme, Elena Belonosova, ...> ;The Lancet. HIV. 2021 Nov 1
• 15 citations
  Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATT...
  Graham H.R. Smith, W Keith Henry, Daniel Podzamczer, Maria Del Mar Masiá, Christopher J Bettacchi, Keikawus Arastéh, Hans Jaeger, Marie-Aude Khuong-Josses, Maria Luisa...> ;Open Forum Infectious Diseases. 2021 Aug 25
• 32 citations
  Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96...
  Onyema Ogbuagu, Peter Ruane, Daniel Podzamczer, Laura C Salazar, Keith Henry, David M Asmuth, David A. Wohl, Richard Gilson, Yongwu Shao, Ramin Ebrahimi, Stephanie Cox...> ;The Lancet. HIV. 2021 Jul 1
• 125 citations
  Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase ...
  , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Lancet. 2020 Dec 19
• 67 citations
  Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
  Giuliano Rizzardini, Edgar T. Overton, Chloe Orkin, Susan Swindells, Keikawus Arastéh, Miguel de Górgolas Hernández-Mora, Vadim Pokrovsky, Pierre Marie Girard, Shinich...> ;Journal of Acquired Immune Deficiency Syndromes. 2020 Dec 1
• 210 citations
  Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
  Susan Swindells, Jaime-Federico Andrade-Villanueva, Gary Richmond, Giuliano Rizzardini, Axel Baumgarten, Mar Masiá, Gulam H Latiff, Vadim Pokrovsky, Fritz Bredeek, Gra...> ;The New England Journal of Medicine. 2020 Mar 4
• 30 citations
  Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disopr...
  Joseph J. Eron, Chloe Orkin, Douglas Cunningham, Federico Pulido, Frank A. Post, Stéphane De Wit, Erkki Lathouwers, Veerle Hufkens, John Jezorwski, Romana Petrovic, Ki...> ;Antiviral Research. 2019 Oct 1
• 120 citations
  Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
  Brinda Emu, Jeffrey Fessel, Shannon Schrader, Princy Kumar, Gary Richmond, Sandra Win, Steven Weinheimer, Christian Marsolais, Stanley Lewis> ;The New England Journal of Medicine. 2018 Aug 16
• 84 citations
  Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United St...
  Deanna Kerrigan, Andrea Mantsios, Miguel Górgolas, María Luisa Montes, Federico Pulido, Cynthia Brinson, Jerome deVente, Gary Richmond, Sarah W. Beckham, Paige Hammond...> ;Plos One. 2018 Jan 5
• 72 citations
  Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat,...
  Chloe Orkin, Jean-Michel Molina, Eugenia Negredo, Jose R. Arribas, Joseph Gathe, Joseph J. Eron, Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, Romana Petrovic, ...> ;The Lancet. HIV. 2018 Jan 1
• 326 citations
  Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority...
  David A. Margolis, Juan González-García, Hans Jürgen Stellbrink, Joseph J. Eron, Yazdan Yazdanpanah, Daniel Podzamczer, Thomas A. Lutz, Jonathan B. Angel, Gary Richmon...> ;Lancet. 2017 Sep 23
• Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.
  Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, Molina JM, Chas J, Durant J, Moreno S, Doroana M, Ait-Khaled M, Huang J, Min S, Song I, Vavro C, Nicho...> ;The Journal of infectious diseases. 2014-01-19
• 55 citations
  Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
  Bisher Akil, Gary Blick, Debbie Hagins, Moti Ramgopal, Gary Richmond, Rafik M Samuel, Naomi Givens, Cindy Vavro, Ivy Song, Brian Wynne, Mounir Ait-Khaled> ;Antiviral Therapy. 2014 Apr 1
• 403 citations
  Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferi...
  , , , , , , , , , , , , , , , , , , , , > ;Lancet. 2013 Aug 24
• 238 citations
  Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
  Joseph J. Eron, Bonaventura Clotet, J. Durant, Christine Katlama, Princy Kumar, Adriano Lazzarin, Isabelle Poizot-Martin, Gary Richmond, Vincent Soriano, Mounir Ait-Kh...> ;The Journal of Infectious Diseases. 2013 Mar 1
• Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRI...
  Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S, SPRING-2 Study Group> ;Lancet (London, England). 2013-01-08
• 3 citations
  Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir
  Richard Elion, Daniel S Berger, Gary Richmond, Michael Sension, Edwin DeJesus, Cimoch Pj, Marty St. Clair, Linda Yau, Belinda Ha> ;HIV Clinical Trials. 2010 May 1
• 44 citations
  Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
  Julian Falutz, Soraya Allas, Jean-Claude Mamputu, Diane Potvin, Donald P. Kotler, Michael Somero, Daniel S Berger, Stephen Brown, Gary Richmond, Jeffrey Fessel, Ralph ...> ;AIDS. 2008 Sep 12
• 23 citations
  Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.
  Richard Elion, Edwin DeJesus, Michael Sension, Daniel S Berger, William J. Towner, Gary Richmond, Marty St. Clair, Linda Yau, Belinda Ha> ;HIV Clinical Trials. 2008 May 1
• 58 citations
  Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.
  Jacob Lalezari, Gopal Yadavalli, Michael F. Para, Gary Richmond, Edwin DeJesus, Stephen J. Brown, Wendy Cai, Cecil Chen, John Zhong, Lu Anne Novello, Michael M. Lederm...> ;The Journal of Infectious Diseases. 2008 Mar 1
• 16 citations
  Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with...
  Pablo Tebas, Nicholas C. Bellos, Christopher Lucasti, Gary Richmond, Eliot Godofsky, Indravadan H. Patel, Yu-Yuan Chiu, Claire Evans, Lucy Rowell, Miklos Salgo> ;Journal of Acquired Immune Deficiency Syndromes. 2008 Mar 1
• 136 citations
  Metabolic effects of a growth hormone-releasing factor in patients with HIV.
  Julian Falutz, Soraya Allas, K Blot, Diane Potvin, Donald P. Kotler, Michael Somero, Daniel S Berger, Stephen J. Brown, Gary Richmond, Jeffrey Fessel, Ralph R. Turner,...> ;The New England Journal of Medicine. 2007 Dec 6
• 57 citations
  Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy.
  Carl Grunfeld, Melanie A. Thompson, Stephen J. Brown, Gary Richmond, Daniel Lee, Norma Muurahainen, Donald P. Kotler> ;Journal of Acquired Immune Deficiency Syndromes. 2007 Jul 1
• Join now to see all

Journal Articles

• Effects of a Growth Hormone Releasing Factor Analogue on Body Composition and Metabolic Indices in HIV-Infected Patients.  
  Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Grinspoon S, New England Journal of Medicine
• Atrial Septal Rupture, Flail Tricupsid Valve, and Complete Heart Block Due to Nonpenetrating Chest Trauma.  
  Thors A, Guarneri R, Costantini G, Richmond G, Annals of Thoracic Surgery
• Recombinant Human Growth Hormone to Treat HIV-Associated Adipose Redistribution Syndrome: 12 Week Induction and 24-Week Maintenance Therapy.  
  Grunfeld C, Thompson M, Brown S, Richmond G, Lee D, Muurahainen N, Kotler D, Journal of Acquired Immune Deficiency Syndromes: JAIDS
• Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice daily dosing with enfuvirtide in HIV-infected subjects.  
  Thompson M, DeJesus E, Richmond G, Wheeler D, Flaherty J, Piliero P, True A, Chiu U, Zhang Y, McFalls E, Miralles D, Patel I, AIDS
• T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.  
  Lalezari JP, Bellos NC, Sathasivam K, Richmond GJ, Cohen CJ, Myers RA Jr, Henry DH, Raskino C, Melby T, Murchison H, J. Infect Dis
• Pharmacodynamic Effects of Zidovudine 600 mg Once/Day Versus 300 mg Twice/Day in Therapy-Naïve Patients Infected with Human Immunodefiency Virus.  
  Ruane P, Richmond G, DeJesus E, Hill-Zabala C, Danehower S, Liao Q, Johnson J, Shaefer M, Pharmacotherapy
• Safety/Tolerability and Efficacy of Abacavir-Containing Combination Therapy in HIV-1 Infected Adults in a Clinical Practice Setting: Results of ZORRO.  
  Ruane P, Kubota M, Williams A, Arroyo J, Canas A, Richmond G, Alsop CA, Yau L, Hessenthaler S, Hernandez J, Infectious Diseases in Clinical Practice
• A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with Abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse tra...  
  Lalezari JP, DeJesus E, Northfelt DW, Richmond GJ, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlosn M, Riddler S, Haas FF..., Antiviral Therapy
• Twice Daily Amprenavir 1200 mg versus Amprenavir 600 mg / Ritonavir 100 mg in combination with at least 2 other antiretroviral drugs in HIV-1 infected patients.  
  Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Lancaster T, Hernandez JE, Pappa KA, BMC Infectious Diseases
• HIV Patient Acceptance of a Needle-Free Device (SeroJet™) for Administering Recombinant Human Growth Hormone in the Treatment of HIV Infection-Associated Cachexia.  
  Murray FT, Muurahainen N, Gertner JM, Williams A, Santos G, Scheperle M, Richmond G, Findelstein J, Nebiolo L, Gaccione, P, Journal of New Developments in Clinical Medicine
• Primary Pulmonary Hypertension and HIV Infection in a Non-Hemophiliac Man.  
  Jacques C, Richmond G, Tierney L, Curtis J, McKerrow J, Warnock M, Human Pathology
• Superior venal caval syndrome: A Complication of Hickman Catheter Insertion in Patients with AIDS.  
  Richmond G, Handweger S, Schoenfeld N, Talavera W, New York State J. of Medicine
• On the Stability of IgE Antibodies.  
  Ovary Z, Itaya T, Santomauro J, Richmond G, J. Immunol. Methods
• Join now to see all

Abstracts/Posters

• Preliminary Results of Dosing of Amdoxovir in Treatment-Experienced Patients.
  Thompson, M, Richmond, G, Kessler, H, Bae A, Sorbel J, Sista N, Adda N and Rousseau F, Conference on Retroviruses and Opportunistic Infections, Boston MA
• T-1249 Demonstrates Potent Antiviral Activity over 10 Day Dosing in Most Patients who Have Failed a Regimen Containing Enfuvirtide (ENF): Planned Interim Analysis of T...
  Miralles GD, Lalezari PH, Bellos N, Richmond G, Zhang Y, Murchison H, Spense R, Raskino C, Demasi RA, 10th Conference on Retroviruses and Opportunistic Infections, Boston MA
• A Week 48 Assessment of a Randomized, Controlled, Open-Label Phase II Trial (T20-206) Evaluating Three Doses of T-20 in PI-Experienced, NNRTI-Naïve Patients Infected w...
  Lalezari J, DeJesus E, Northfelt D, Richmond G, Delehanty J, Demasi R, Salgo M, 9th Conference on Retroviruses and Opportunistic Infections, Seattle WA
• Efficacy and Safety of APV/RTV 600/100 mg BID Compared to APV 1200 mg BID in ART experienced and naïve subjects: ESS40011.
  Nadler J, Gathe J, Pollard R, Richmond G, Liao Q, Lancaster T, Griffith S, Pappa K, Hernandez J, 14th International AIDS Conference, Barcelona, Spain
• Geotypic (GT) and Virtual Phenotypic (vPT) Correlates of Virologic Response to Abacavir (ABC)-based Therapy in the ZORRO Trial (ESS40009).
  Ruane P, Hernandez J, Richmond G, Williams A, Fralich T, Yau L, Hessenthaler S, Lanier ER, 14th International AIDS Conference, Barcelona, Spain
• Pharmacodynamic effects of zidovudine 600 mg once daily versus zidovudine 300 mg twice daily in therapy-naïve HIV-infected patients (COD20002).
  Ruane P, Richmond G, DeJesus E, Hill-Zabala C, Danehower S, Liao Q, Johnson J, Schaeefer M, 14th International AIDS Conference, Barcelona, Spain
• The Use of Recombinant Human Growth Hormone for Dorsocervical Fat Pad Accumulation in a Patient on Highly Active Antiretroviral Therapy.
  Richmond G, Appleby V, Strawbridge T, Fourteenth Annual Conference Association of Nurses in AIDS Care, Minneapolis, MN
• Safety and Efficacy of Recombinant Human Growth Hormone Serostim® for HIV Associated Wasting in the Era of Highly Active Antiretroviral Therapy.
  Richmond G, Nebiolo L, Rosen A, Finkelstein J, Landy H, Muurahainen, Fourth International Conference on Nutrition and HIV Infection, Cannes, France
• Efficacy and Safety of MDL 28,574A in HIV-Positive Patients with Baseline CD4 Values of 301-500.
  Richmond G, Zolnouni P, Stall J, McPherson M, Hamedani P, Cross V, XI International Conference on AIDS, Vancouver Canada
• Home Infusion Therapy in the Management of HIV Disease using the PAS-Port™ Catheter.
  Richmond G, Appleby V, III Osterreichischen AIDS-Kongress, Vienna, Austria
• Prophylaxis with Inhaled Pentamidine does not Diminish the Yield of Sputum Induction for Diagnosis of Pneumocystis Carinii Pneumonia. 1991 International Conference of ...
  Richmond G, Imoto E, Doherty J, Beck J, Brown J, American Review of Respiratory Diseases
• Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Quad) Demonstrates Comparable Efficacy and Favorable Tolerability to Efavirenz/Emtricitabine/Tenofovir DF in Patien...
  Richmond G, Ruane P, Robbins W, Bredeek F, Shalit P, Hardy D, Workowski K, Rhee M, Piontkowsky D, ICAAC
• Intranasal Cryptococcal Nodule with Disseminated Disease.
  Markwart N, Richmond G, Poster presentation Broward General Medical Center Annual Resident Research Competition
• HIV Integrase Resistance and Phenotypic Susceptibility to Dolutegravir (DTG, S/GSK1349572) for Subjects with Virologic Failure on Raltegravir (RAL).
  Cloete B, Katlama C, Soriano V, Lazzarin A, Richmond G, Huang J, Vavro CL, Underwood MR, Ait-Khaled M, Nichols, W, 9th European Workshop on HIV and Hepatitis
• Dolutegravir (DTG, S/GSK1349572) in Subjects with HIV Exhibiting Raltegravir (RAL) Resistance: Functional Monotherapy Results of VIKING Study Cohort II.
  Eron J, Kumar, P, Lazzarin A, Richmond G, Soriano V, Huang J, Vavro C, Ait-Khaled M, Min S, Yeo J, 18th Conference on Retroviruses and Opportunistic Infections
• Activity of Next Generation Integrase Inhibitor (INI)S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Initial Results of VIKING Study (ING112961).
  Eron J, Durant J, Poizot-Martin I, Reynes J, Soriano V, Kumar P, Richmond G, Vittecoq D, Fujiwara T, Ait-Khaled M, Mins, Thomas D, Cuffe R, Yeo J, XVIII International AIDS Conference, Vienna, Austria
• Once Daily S/GSK1379572 as Part of Combination Therapy in Antiretroviral Naïve Adults: Rapid and Potent Antiviral Responses in the interim 16-Week Analysis from SPRING...
  Arribas J, Lazzarin A, Raffi F, Rakhmanova A, Richmond G, Rockstroh J, van Lunzen J, Young B, Almond S, Brothers C, Min S, Nichols G, XVIII International AIDS Conference, Vienna, Austria
• Dolutegravir (DTG, S/GSK1349572) treatment of HIV subjects with raltegravir resistance: viral suppression at Week 24 in the VIKING study.
  Soriano V, Cox J, Eron J, Kumar P, Katlama C, Lazzarin A, Poizot-Martin I, Richmond G, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J, 13th European AIDS Conference, Belgrade Serbia
• Pharmacokinetics and Safety of Novel 100 mg Tablet Formulation of MPC-4326 in Subjects with HIV Infection.
  Lalezari J, Richmond G, Thompson M, Cohen C, Fidler M, Balch A, Beelen A, 49th ICAAC
• Pharmacokinetics and Safety in Healthy and HIV- Infected Subjects and Short-Term Antiviral Efficacy of S/GSK1265744, a Next Generation Once Daily HIV Integrase Inhibitor.
  Min S, DeJesus E, McCurdy L, Richmond G, Torres J, Ford S, Chen S, Lou Y, Bomar M, Cyr T, St. Clair M, Fujiwara T, Piscitelli S, 49th ICAAC, Oral Presentation
• A Phase II Safety and Efficacy Study of Bevirimat (BMV) in Heavily Treatment Experienced HIV+ Patients Identifies the Target Phase III Study Profile.
  Lalezari J, McCallister S, Gigliotti M, Cohen C, Elion R, Brinson C, Richmond G, Thompson M, Martin D, ICAAC/ISDA
• HIV-1 Gag Polymorphisms Determine Treatment Response to Bevirimat (PA- 456).
  McCallister S, Lalezari J, Richmond G, Thompson M, Harrigan R, Martin D, Salzwedel K, Allaway G, Sitges Resistance Workshop
• Data on 52-Week Safety and Efficacy of Tesamorelin (TH9507), a Growth Hormone Releasing Factor Analogue, in HIV-Infected Patients with Abdominal Fat Accumulation.
  Falutz J, Allas S, Mamputu JC, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Grinspoon S, 15th Conference on Retroviruses and Opportunistic Infections
• Simplified maintenance therapy with ABC/3TC + ATC after ABC/3TC + ATV/RTV Induction for 48 weeks.
  Elion R, Berger D, Richmond G, Sension M, DeJesus E, Cimoch P, Yau L, Ha B, Conference of American College of Clinical Pharmacy
• Relationship between baseline visceral adipose tissue (VAT) and VAT loss during reatment with recombinant human growth hormone (r- hhGH) in patients with human immunod...
  Richmond G, Kotler D, Freedland E, Infectious Disease Society of America Annual Meeting
• Join now to see all